Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17466002 | 0.83 | ALDH1A1 (0.48) | CASRAOC3L3MBTL1ACHECES2 | |
| SCHEMBL1883318 | 0.82 | ALDH1A1 (0.47) | CASRL3MBTL1KMT2ACA1CA2 | |
| SCHEMBL15978566 | 0.82 | PTGS1 (0.57) | KMT2AALDH1A1 | |
| SCHEMBL7035268 | 0.82 | PTGS1 (0.57) | KMT2AALDH1A1 | |
| SCHEMBL31542598 | 0.82 | PTGS1 (0.57) | KMT2AALDH1A1 | |
| SCHEMBL24106552 | 0.82 | PTGS1 (0.57) | KMT2AALDH1A1 | |
| SCHEMBL7265586 | 0.82 | AOC3 (0.45) | CASRAOC3L3MBTL1ACHETAAR1 | |
| SCHEMBL3914361 | 0.82 | SGMS2 (0.40) | CASRAOC3L3MBTL1ALDH1A1 | |
| SCHEMBL910481 | 0.81 | L3MBTL1 (0.47) | CASRAOC3L3MBTL1ACHETAAR1 | |
| SCHEMBL4713706 | 0.80 | ALDH1A1 (0.48) | KMT2AALDH1A1CYP3A4PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025010311-A1 | UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-01-09 | — | — | WO | disclosed |
| CN-118955261-A | Synthesis process of phloretin and derivative thereof and application of phloretin and derivative thereof as antioxidant in plastic products | 营口风光新材料股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2022-02-22 | — | — | US | disclosed |
| US-20210087213-A1 | DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3715343-A1 | DIPHENYLAMINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2020-09-30 | — | — | EP | disclosed |
| EP-1951675-B1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-1951675-B1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8242145-B2 | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242145-B2 | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-1951675-A1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | Brystol-Myers Squibb Company (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007047991-A1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047991-A1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | CASR 552/4885AOC3 3880/4885L3MBTL1 3484/4885 |
| US-20210087213-A1 | DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | ALK, BRAF, MUSK | CASR 4297/4885AOC3 4769/4885L3MBTL1 1156/4885 |
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER1 | CASR 968/4885AOC3 2552/4885L3MBTL1 4114/4885 |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | NR1H2, NR1H3, NR1I2 | CASR 1839/4885AOC3 4578/4885L3MBTL1 1226/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | CASR 2454/4885AOC3 2269/4885L3MBTL1 3459/4885 |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | ALK, BRAF, MUSK | CASR 4032/4885AOC3 4708/4885L3MBTL1 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.